[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"condition:myelofibrosis":3},{"name":4,"total":5,"recruiting":6,"trials":7,"biomarkers":311,"states":324},"Myelofibrosis",61,55,[8,16,23,29,36,42,49,55,61,67,73,79,85,91,97,103,110,116,122,128,134,140,146,152,158,164,170,176,182,188,194,200,206,212,217,223,229,235,241,246,252,258,264,270,276,282,288,294,299,305],{"nct_id":9,"title":10,"phases":11,"status":13,"updated_at":14,"content_modified":15},"NCT05535764","Allogeneic Hematopoietic Cell Transplantation With Pegylated Interferon Alfa-2a for Primary and Secondary Myelofibrosis",[12],"Phase 1","RECRUITING","2026-08-26T02:18:29.369233Z","2026-06-18T12:24:02.363291Z",{"nct_id":17,"title":18,"phases":19,"status":13,"updated_at":21,"content_modified":22},"NCT06414681","Combination of Tagraxofusp With Pacritinib in Patients With Intermediate-1 or Higher Myelofibrosis, Who Have Had Prior Therapy With the Approved JAK Inhibitors or in Which Therapy With the Approved JAK Inhibitors is Not Appropriate, Contraindicated or Declined",[20],"Early Phase 1","2026-08-26T02:15:52.238965Z","2026-05-13T02:55:06.490620Z",{"nct_id":24,"title":25,"phases":26,"status":13,"updated_at":27,"content_modified":28},"NCT07379125","Therapeutic RSK1 Targeting in Myelofibrosis",[12],"2026-08-26T02:17:09.131534Z","2026-05-05T02:43:29.570409Z",{"nct_id":30,"title":31,"phases":32,"status":13,"updated_at":34,"content_modified":35},"NCT07281781","Treating Anemia in Myelofibrosis With Repurposed Drugs (Nelfinavir) That Restore Iron Delivery to the Bone Marrow",[33],"Phase 1\u002FPhase 2","2026-08-26T02:18:15.214990Z","2026-05-05T02:43:29.526219Z",{"nct_id":37,"title":38,"phases":39,"status":13,"updated_at":40,"content_modified":41},"NCT07104799","Momelotinib During and After HCT in Myelofibrosis",[12],"2026-08-26T02:17:45.190188Z","2026-05-05T02:43:29.498826Z",{"nct_id":43,"title":44,"phases":45,"status":13,"updated_at":47,"content_modified":48},"NCT05835466","Reparixin in Patients With Myelofibrosis Myeloproliferative Neoplasms Research Consortium (MPN-RC 120)",[46],"Phase 2","2026-08-26T02:18:05.435729Z","2026-05-05T02:43:29.353927Z",{"nct_id":50,"title":51,"phases":52,"status":13,"updated_at":53,"content_modified":54},"NCT05371964","A Study to Evaluate the Safety, Pharmacokinetics, Pharmacodynamics and Clinical Activity of Imetelstat in Combination With Ruxolitinib in Participants With Myelofibrosis",[12],"2026-08-26T02:18:17.950264Z","2026-05-05T02:43:29.073074Z",{"nct_id":56,"title":57,"phases":58,"status":13,"updated_at":59,"content_modified":60},"NCT05423691","Leading in MPNs Beyond Ruxolitinib in Combo With T-Regs",[12],"2026-08-26T02:15:20.225313Z","2026-05-05T02:43:28.879213Z",{"nct_id":62,"title":63,"phases":64,"status":13,"updated_at":65,"content_modified":66},"NCT06345495","High Dose Ruxolitinib and Allogeneic Stem Cell Transplantation in Myelofibrosis Patients With Splenomegaly",[46],"2026-08-26T02:19:00.742020Z","2026-05-05T02:43:28.742229Z",{"nct_id":68,"title":69,"phases":70,"status":13,"updated_at":71,"content_modified":72},"NCT06034002","A Study to Evaluate INCA033989 Administered as a Monotherapy or in Combination With Ruxolitinib in Participants With Myeloproliferative Neoplasms",[12],"2026-08-26T02:18:51.009190Z","2026-05-05T02:43:28.650417Z",{"nct_id":74,"title":75,"phases":76,"status":13,"updated_at":77,"content_modified":78},"NCT07128381","Phase I\u002FII Clinical Trial of Axatilimab, a CSF1R Monoclonal Antibody, in Combination With Ruxolitinib as Therapy for Patients With Myelofibrosis (MF) and Chronic Myelomonocytic Leukemia (CMML)",[33],"2026-08-26T02:19:17.380174Z","2026-05-05T02:43:28.625623Z",{"nct_id":80,"title":81,"phases":82,"status":13,"updated_at":83,"content_modified":84},"NCT04176198","A Study of Oral Nuvisertib (TP-3654) in Patients With Myelofibrosis",[33],"2026-08-26T02:17:48.768272Z","2026-05-05T02:43:28.349151Z",{"nct_id":86,"title":87,"phases":88,"status":13,"updated_at":89,"content_modified":90},"NCT07250646","A Study of Rebecsinib for Patients With Relapsed\u002FRefractory Secondary Acute Myeloid Leukemia or High Risk Myelofibrosis",[12],"2026-08-26T02:16:14.341106Z","2026-05-05T02:43:27.984688Z",{"nct_id":92,"title":93,"phases":94,"status":13,"updated_at":95,"content_modified":96},"NCT07008118","A Study to Evaluate INCA035784 in Participants With Myeloproliferative Neoplasms",[12],"2026-08-26T02:18:09.641312Z","2026-05-05T02:43:27.965447Z",{"nct_id":98,"title":99,"phases":100,"status":13,"updated_at":101,"content_modified":102},"NCT07469891","A Phase 1 Study of PRT12396 in Participants With Select Myeloproliferative Neoplasms",[12],"2026-08-26T02:16:06.684983Z","2026-05-05T02:43:27.656131Z",{"nct_id":104,"title":105,"phases":106,"status":13,"updated_at":108,"content_modified":109},"NCT06479135","Study of Navtemadlin add-on to Ruxolitinib in JAK Inhibitor-Naïve Patients With Myelofibrosis Who Have a Suboptimal Response to Ruxolitinib",[107],"Phase 3","2026-08-26T02:18:42.501841Z","2026-05-05T02:43:27.517340Z",{"nct_id":111,"title":112,"phases":113,"status":13,"updated_at":114,"content_modified":115},"NCT07228624","Ruxolitinib Before, During and After Hematopoietic Cell Transplant in Older Patients With Myelofibrosis and Myelodysplastic Syndrome\u002FMyeloproliferative Neoplasm Overlap Syndromes",[46],"2026-08-26T02:15:46.655893Z","2026-05-05T02:43:26.852525Z",{"nct_id":117,"title":118,"phases":119,"status":13,"updated_at":120,"content_modified":121},"NCT05980806","A Study of Selinexor Monotherapy in Subjects With JAK Inhibitor-naïve Myelofibrosis and Moderate Thrombocytopenia",[46],"2026-08-26T02:19:02.550788Z","2026-05-05T02:43:26.770211Z",{"nct_id":123,"title":124,"phases":125,"status":13,"updated_at":126,"content_modified":127},"NCT06150157","A Study of JNJ-88549968 for the Treatment of Calreticulin (CALR)-Mutated Myeloproliferative Neoplasms",[12],"2026-08-26T02:16:23.080181Z","2026-04-29T02:57:57.158454Z",{"nct_id":129,"title":130,"phases":131,"status":13,"updated_at":132,"content_modified":133},"NCT06773195","A Study of Ruxolitinib in Combination With Ulixertinib in People With Myelofibrosis",[33],"2026-08-26T02:17:33.002248Z","2026-07-30T01:46:14.433209Z",{"nct_id":135,"title":136,"phases":137,"status":13,"updated_at":138,"content_modified":139},"NCT05025488","Mutant CALR-peptide Based Vaccine in Patients With Mutated CALR Myeloproliferative Neoplasm",[12],"2026-08-26T02:15:23.202838Z","2026-05-05T02:43:29.683710Z",{"nct_id":141,"title":142,"phases":143,"status":13,"updated_at":144,"content_modified":145},"NCT04064060","A Study to Evaluate Long-term Safety in Participants Who Have Participated in Other Luspatercept (ACE-536) Clinical Trials",[107],"2026-08-26T02:16:58.658552Z","2026-05-05T02:43:28.876012Z",{"nct_id":147,"title":148,"phases":149,"status":13,"updated_at":150,"content_modified":151},"NCT03326310","Selumetinib and Azacitidine in High Risk Chronic Blood Cancers",[12],"2026-08-26T02:18:01.700186Z","2026-05-05T02:43:28.822764Z",{"nct_id":153,"title":154,"phases":155,"status":13,"updated_at":156,"content_modified":157},"NCT05280509","Study of TL-895 Combined With Ruxolitinib in JAKi Treatment-Naïve MF Subjects and Subjects With MF Who Have a Suboptimal Response to Ruxolitinib",[33],"2026-08-26T02:16:36.513735Z","2026-05-05T02:43:28.627507Z",{"nct_id":159,"title":160,"phases":161,"status":13,"updated_at":162,"content_modified":163},"NCT06351631","A Study to Evaluate Safety and Efficacy of Bomedemstat (MK-3543-017)",[107],"2026-08-26T02:16:18.872924Z","2026-05-05T02:43:27.946262Z",{"nct_id":165,"title":166,"phases":167,"status":13,"updated_at":168,"content_modified":169},"NCT05488548","Dual BET and CBP\u002Fp300 Inhibitor in Patients With Targeted Advanced Solid Tumors and Hematological Malignancies",[12],"2026-08-26T02:16:57.705506Z","2026-05-05T02:43:27.844024Z",{"nct_id":171,"title":172,"phases":173,"status":13,"updated_at":174,"content_modified":175},"NCT06834282","CER-1236 in Patients With Acute Myeloid Leukemia (AML), Myelodysplastic Syndrome (MDS), and Myelofibrosis (MF)",[12],"2026-08-26T02:18:21.216897Z","2026-05-05T02:43:27.841989Z",{"nct_id":177,"title":178,"phases":179,"status":13,"updated_at":180,"content_modified":181},"NCT06313593","A Study to Evaluate the Safety, Tolerability of INCB160058 in Participants With Myeloproliferative Neoplasms",[12],"2026-08-03T03:34:20.548203Z","2026-05-05T02:43:27.444739Z",{"nct_id":183,"title":184,"phases":185,"status":13,"updated_at":186,"content_modified":187},"NCT07441694","Study of INCA036978 in Participants With Myeloproliferative Neoplasms",[12],"2026-08-26T02:16:20.336282Z","2026-05-05T02:43:27.275822Z",{"nct_id":189,"title":190,"phases":191,"status":13,"updated_at":192,"content_modified":193},"NCT06265584","Trial of 2 Step ATG for Prevention of Acute GVHD Post Allogeneic Stem Cell Transplant",[46],"2026-08-26T02:16:56.877406Z","2026-05-05T02:43:27.255093Z",{"nct_id":195,"title":196,"phases":197,"status":13,"updated_at":198,"content_modified":199},"NCT05123365","An Optimal Dose Finding Study of N-Acetylcysteine in Patients With Myeloproliferative Neoplasms",[33],"2026-08-26T02:15:11.740957Z","2026-05-05T02:43:26.953012Z",{"nct_id":201,"title":202,"phases":203,"status":13,"updated_at":204,"content_modified":205},"NCT06541249","MethoTRExATE in MyelOpRolifErative Neoplasms (TREATMORE) Trial",[46],"2026-08-26T02:16:04.914942Z","2026-04-29T02:57:57.065431Z",{"nct_id":207,"title":208,"phases":209,"status":13,"updated_at":210,"content_modified":211},"NCT05320198","Study of DISC-0974 (RALLY-MF) in Participants With Myelofibrosis or Myelodysplastic Syndrome and Anemia",[33],"2026-08-26T02:18:53.782384Z","2026-07-24T01:27:14.872106Z",{"nct_id":213,"title":214,"phases":215,"status":13,"updated_at":186,"content_modified":216},"NCT06712810","Q702 for the Treatment of Patients With Hematologic Malignancies",[12],"2026-05-05T02:43:29.581486Z",{"nct_id":218,"title":219,"phases":220,"status":13,"updated_at":221,"content_modified":222},"NCT05031897","Two Step Haplo With Radiation Conditioning",[46],"2026-08-26T02:16:32.589113Z","2026-05-05T02:43:29.158573Z",{"nct_id":224,"title":225,"phases":226,"status":13,"updated_at":227,"content_modified":228},"NCT06063486","Curcumin to Improve Inflammation and Symptoms in Patients With Clonal Cytopenia of Undetermined Significance, Low Risk Myelodysplastic Syndrome, and Myeloproliferative Neoplasms",[46],"2026-08-26T02:16:17.877565Z","2026-05-05T02:43:29.075022Z",{"nct_id":230,"title":231,"phases":232,"status":13,"updated_at":233,"content_modified":234},"NCT06008808","Ruxolitinib With and Without CTLA-4 Ig Abatacept for the Prophylaxis of Graft-Versus-Host Disease and Cytokine Release Syndrome After T-cell Replete Haploidentical Peripheral Blood Hematopoietic Cell Transplantation",[12],"2026-08-26T02:16:33.772093Z","2026-05-05T02:43:28.872786Z",{"nct_id":236,"title":237,"phases":238,"status":13,"updated_at":239,"content_modified":240},"NCT06859424","A Platform Protocol to Investigate Post-Transplant Cyclophosphamide-Based Graft-Versus-Host Disease Prophylaxis in Patients With Hematologic Malignancies Undergoing Mismatched Unrelated Donor Peripheral Blood Stem Cell Transplantation",[46],"2026-08-26T02:15:31.806698Z","2026-05-05T02:43:28.740200Z",{"nct_id":242,"title":243,"phases":244,"status":13,"updated_at":89,"content_modified":245},"NCT03314974","Myeloablative Allo HSCT With Related or Unrelated Donor for Heme Disorders",[46],"2026-05-05T02:43:28.206546Z",{"nct_id":247,"title":248,"phases":249,"status":13,"updated_at":250,"content_modified":251},"NCT05805605","Allo HSCT Using RIC and PTCy for Hematological Diseases",[46],"2026-08-26T02:17:29.353236Z","2026-05-05T02:43:28.075410Z",{"nct_id":253,"title":254,"phases":255,"status":13,"updated_at":256,"content_modified":257},"NCT06398457","Darzalex Faspro (Daratumumab and Hyaluronidase-fihj) Before Standard Desensitization and Allogeneic Peripheral Blood Stem Cell Transplantation in Adult Patients at High-risk for Primary Graft Failure Secondary to Donor Specific Antibodies",[20],"2026-08-26T02:15:53.461103Z","2026-05-05T02:43:27.839395Z",{"nct_id":259,"title":260,"phases":261,"status":13,"updated_at":262,"content_modified":263},"NCT04771572","Study of Oral Administration of LP-118 in Patients With Relapsed or Refractory CLL, SLL, MDS, MDS\u002FMPN, AML, CMML-2, MPN-BP, ALL, MF, NHL, RT, MM or T-PLL.",[12],"2026-08-26T02:18:06.247899Z","2026-05-05T02:43:27.598768Z",{"nct_id":265,"title":266,"phases":267,"status":13,"updated_at":268,"content_modified":269},"NCT03964506","Hyperbaric Oxygen Therapy and Allogeneic Peripheral Blood Stem Cell (PBSC) Transplant",[20],"2026-08-26T02:18:44.395098Z","2026-05-05T02:43:27.480390Z",{"nct_id":271,"title":272,"phases":273,"status":13,"updated_at":274,"content_modified":275},"NCT06059391","CMV-MVA Triplex Vaccination in HLA-Matched Related Stem Cell Donors for the Prevention of CMV Infection in Patients Undergoing Hematopoietic Stem Cell Transplant",[46],"2026-08-26T02:16:01.910993Z","2026-05-05T02:35:31.868600Z",{"nct_id":277,"title":278,"phases":279,"status":13,"updated_at":280,"content_modified":281},"NCT05436418","The Lowest Effective Dose of Post-Transplantation Cyclophosphamide in Combination With Sirolimus and Mycophenolate Mofetil as Graft-Versus-Host Disease Prophylaxis After Reduced Intensity Conditioning and Peripheral Blood Stem Cell Transplantation",[33],"2026-08-26T02:17:18.747857Z","2026-05-05T02:35:31.635324Z",{"nct_id":283,"title":284,"phases":285,"status":13,"updated_at":286,"content_modified":287},"NCT07020533","A Vaccine (CMV-MVA Triplex Vaccine) for the Enhancement of CMV-Specific Immunity and the Prevention of CMV Viremia in Patients Undergoing Haploidentical Hematopoietic Stem Cell Transplant",[12],"2026-08-26T02:18:31.944757Z","2026-05-05T02:43:28.960514Z",{"nct_id":289,"title":290,"phases":291,"status":13,"updated_at":292,"content_modified":293},"NCT07623161","A Study to Compare Elritercept to Placebo in Adults With Myelofibrosis and Anemia Who Are Taking Ruxolitinib",[107],"2026-08-26T02:17:44.240289Z","2026-07-24T01:27:14.910530Z",{"nct_id":295,"title":296,"phases":297,"status":13,"updated_at":250,"content_modified":298},"NCT02934477","Prospective Assessment of Allogeneic Hematopoietic Cell Transplantation in Patients With Myelofibrosis",[],"2026-05-13T02:55:06.103558Z",{"nct_id":300,"title":301,"phases":302,"status":13,"updated_at":303,"content_modified":304},"NCT01973881","Quantitative MRI for Myelofibrosis",[],"2026-08-26T02:17:34.833510Z","2026-05-13T02:55:06.080134Z",{"nct_id":306,"title":307,"phases":308,"status":13,"updated_at":309,"content_modified":310},"NCT02677064","Identify Barriers to Allogeneic Hematopoietic Stem Cell Transplantation in Patients With Newly Diagnosed and Relapsed Acute Leukemia",[],"2026-08-26T02:18:00.873391Z","2026-07-30T01:46:14.456283Z",[312,316,320],{"biomarker":313,"count":314,"slug":315},"CALR Gene",5,"calr-gene",{"biomarker":317,"count":318,"slug":319},"HLA Complex",4,"hla-complex",{"biomarker":321,"count":322,"slug":323},"JAK2 Gene",3,"jak2-gene",[325,329,333,337,341,345,348,351,355,359,362,366,369,372,375,378,381,385,388,391,395,398,401,404],{"state":326,"count":327,"slug":328},"New York",25,"new-york",{"state":330,"count":331,"slug":332},"California",23,"california",{"state":334,"count":335,"slug":336},"Texas",22,"texas",{"state":338,"count":339,"slug":340},"Florida",15,"florida",{"state":342,"count":343,"slug":344},"Massachusetts",14,"massachusetts",{"state":346,"count":343,"slug":347},"North Carolina","north-carolina",{"state":349,"count":343,"slug":350},"Ohio","ohio",{"state":352,"count":353,"slug":354},"Pennsylvania",12,"pennsylvania",{"state":356,"count":357,"slug":358},"Michigan",10,"michigan",{"state":360,"count":357,"slug":361},"Tennessee","tennessee",{"state":363,"count":364,"slug":365},"Colorado",8,"colorado",{"state":367,"count":364,"slug":368},"Georgia","georgia",{"state":370,"count":364,"slug":371},"Maryland","maryland",{"state":373,"count":364,"slug":374},"Minnesota","minnesota",{"state":376,"count":364,"slug":377},"Utah","utah",{"state":379,"count":364,"slug":380},"Washington","washington",{"state":382,"count":383,"slug":384},"Alabama",7,"alabama",{"state":386,"count":383,"slug":387},"Arizona","arizona",{"state":389,"count":383,"slug":390},"Missouri","missouri",{"state":392,"count":393,"slug":394},"Illinois",6,"illinois",{"state":396,"count":393,"slug":397},"Kansas","kansas",{"state":399,"count":314,"slug":400},"New Jersey","new-jersey",{"state":402,"count":314,"slug":403},"Oregon","oregon",{"state":405,"count":318,"slug":406},"Virginia","virginia"]